Page last updated: 2024-11-06

adamantanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adamantanone is a bicyclic ketone with a cage-like structure. It is known for its high melting point and its use as a precursor to various pharmaceutical compounds. The synthesis of adamantanone involves the oxidation of adamantane, often using chromic acid or potassium permanganate. Adamantanone is a versatile building block in organic synthesis due to its unique structural properties and reactivity. It has been studied for its potential in the development of new pharmaceuticals, including anti-inflammatory agents, antiviral compounds, and antitumor agents. Its rigid structure and reactivity make it an attractive target for drug discovery research.'

adamantanone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64151
CHEMBL ID2041316
CHEBI ID40611
SCHEMBL ID71132
SCHEMBL ID4721541
SCHEMBL ID10285140
SCHEMBL ID14791313
SCHEMBL ID14094609
MeSH IDM0042244

Synonyms (62)

Synonym
AC-16093
nsc 126345
tricyclo(3.3.1.13,7)decanone
brn 1210235
tricyclo(3.3.1.13,7)decan-2-one
tricyclo(3.3.1.1(sup 3,7))decanone
ai3-34003
einecs 211-847-2
adamantanone
tricyclo[3.3.1.13,7]decanone
nsc126345
2-adamantone
2-adamantanone ,
700-58-3
2-oxoadamantane
nsc-126345
tricyclo[3.3.1.1(3,7)]decanone
C0604
CHEBI:40611 ,
adamantan-2-one
tricyclo[3.3.1.1(3,7)]decan-2-one
DB02125
2-adamantanone, reagentplus(r), 99%
STK325358
tricyclo[3.3.1.1~3,7~]decan-2-one
A0719
AKOS001086414
A836754
AKOS005256545
CHEMBL2041316
unii-ui7w503l08
ui7w503l08 ,
FT-0600862
PS-3002
SCHEMBL71132
SY005737
mfcd00074737
tricyclo[3.3.1.13,7 ]decan-2-one
2 -adamantanon
2-admantanone
2-adamantanon
SCHEMBL4721541
SCHEMBL10285140
SCHEMBL14791313
Q-200226
SCHEMBL14094609
STR01057
DTXSID9022108
F0001-1816
AC-8482
AC7531
tricyclo[3.3.1.13,7]decan-2-one
2-adamantanone, vetec(tm) reagent grade, 98%
CS-W019662
tricyclo[3.3.1.1(sup 3,7)]decanone
(1r,3r,5r,7r)-tricyclo[3.3.1.1~3,7~]decan-2-one
Q27093191
FS-4094
HY-Y0421
EN300-16796
tricyclo[3.3.1.1^3,^7]decan-2-one
Z56782489
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
adamantanonesA member of the class of adamantanes that is adamantane carrying at least one oxo group at unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID668903Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID668905Inhibition of Influenza A Virus M2 proton channel V27A mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID668906Inhibition of Influenza A Virus M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID668904Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's1 (6.67)18.2507
2000's4 (26.67)29.6817
2010's5 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.98 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index38.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]